POMALYST® (pomalidomide) is a thalidomide analogue indicated, in combination with dexamethasone, for adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.
IN A PIVOTAL TRIAL IN WHICH 89% OF PATIENTS WERE REFRACTORY TO lenalidomide
Nearly 60% of patients responded to
POMALYST® (pomalidomide) + dex + daratumumab.
Nearly 60% ORR and >1 year median DoR with
POMALYST + dex + dara.

Information about POMALYST + dexamethasone + daratumumab does not appear in the POMALYST Prescribing Information (PI). Please see the daratumumab full PI for a discussion of Important Safety Information at www.darzalex.com.
POMALYST + dexamethasone + daratumumab Indication
POMALYST + dexamethasone + daratumumab is indicated for the treatment of adult patients with MM who have received at least two prior therapies including lenalidomide and a PI.
WARNINGS AND PRECAUTIONS FOR DARATUMUMAB (cont’d)
- Neutropenia: Monitor complete blood cell counts periodically during treatment. Monitor patients with neutropenia for signs of infection. Consider withholding daratumumab until recovery of neutrophils.
- Thrombocytopenia: Monitor complete blood cell counts periodically during treatment. Consider withholding daratumumab until recovery of platelets.
- Interference with Determination of Complete Response: Daratumumab can interfere with the determination of complete response and of disease progression in some patients with IgG kappa myeloma protein.
- Embryo-Fetal Toxicity: Can cause fetal harm. Advise pregnant women of the potential risk to a fetus and advise females of reproductive potential to use effective contraception.
CI, confidence interval; CR, complete response; dara, daratumumab; DoR, duration of response; IMWG, International Myeloma Working Group; MM, multiple myeloma; ORR, overall response rate; PI, proteasome inhibitor; PR, partial response; sCR, stringent complete response; VGPR, very good partial response.
Reference: 1. Daratumumab [package insert]. Horsham, PA: Janssen Biotech, Inc.